

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Topic selection and scoping UroShield for preventing catheter-associated urinary tract infections

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

1. Have any potential equality issues been identified during the development of the topic briefing note or during selection, and, if so, what are they?

UroShield is not intended for use in children. In adults, women are more likely to develop a catheter-associated urinary tract infection than men. Cerebrovascular disease and paraplegia are associated with an increasing likelihood of catheter-associated urinary tract infection. Sex and disability are protected characteristics under the Equality Act. Urinary tract infection is an important cause of morbidity and antibiotic use in older adults. Age is a protected characteristic under the Equality Act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

No equality issues have been identified.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No equality issues have been identified.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No equality issues have been identified.

Approved by Associate Director: Anastasia Chalkidou

Date: 10 May 2021